WO1998046275A3 - Vehicule du pool sanguin pour agents d'imagerie lipophiles - Google Patents

Vehicule du pool sanguin pour agents d'imagerie lipophiles Download PDF

Info

Publication number
WO1998046275A3
WO1998046275A3 PCT/US1998/007239 US9807239W WO9846275A3 WO 1998046275 A3 WO1998046275 A3 WO 1998046275A3 US 9807239 W US9807239 W US 9807239W WO 9846275 A3 WO9846275 A3 WO 9846275A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood
lipophilic
modified
imaging agents
soluble
Prior art date
Application number
PCT/US1998/007239
Other languages
English (en)
Other versions
WO1998046275A2 (fr
Inventor
Raymond E Counsell
Marc A Longino
Jamey P Weichert
Original Assignee
Univ Michigan
Raymond E Counsell
Marc A Longino
Jamey P Weichert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Raymond E Counsell, Marc A Longino, Jamey P Weichert filed Critical Univ Michigan
Priority to CA002286138A priority Critical patent/CA2286138A1/fr
Priority to EP98918097A priority patent/EP0973553A2/fr
Priority to AU71087/98A priority patent/AU7108798A/en
Priority to JP54410898A priority patent/JP2001524957A/ja
Publication of WO1998046275A2 publication Critical patent/WO1998046275A2/fr
Publication of WO1998046275A3 publication Critical patent/WO1998046275A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines

Abstract

L'invention a trait à une émulsion huile-dans-eau du type lipoprotéine à modification de surface utile en tant que véhicule d'apport sélectif du pool sanguin pour agents d'imagerie lipophiles ou dérivés lipophiles d'agents d'imagerie hydrosolubles. Ce véhicule d'apport sélectif du pool sanguin, qui demeure dans le sang pendant plusieurs heures, ne fait montre que d'une séquestration hépatique précoce très réduite et est éliminé dans les 24 heures. Le diamètre moyen de la phase huileuse est inférieur à 150 nm, ce qui réduit au maximum une séquestration par le système réticulo-endothélial. La surface de la phase huileuse est modifiée par un phospholipide à modification polyéthyl glycol pour empêcher l'existence d'interactions normales avec les sites récepteurs des hépatocytes. En imagerie radiographique, il est possible d'introduire dans le noyau lipophile d'une particule d'émulsion du type lipoprotéine des triglycérides radioactives ou stables, synthétiques ou semi-synthétiques polyhalogénées, 2-oléoyglycérol-1,3bis[7-(3-amino-2,4,6-tri-iodophényl)heptanoate] par exemple, ou des dérivés lipidiques solubles d'agents de contraste hydrosolubles classiques, notamment des esters aliphatiques d'acide iopanoïque, diatrizoïque et acétrizoïque.
PCT/US1998/007239 1997-04-11 1998-04-10 Vehicule du pool sanguin pour agents d'imagerie lipophiles WO1998046275A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002286138A CA2286138A1 (fr) 1997-04-11 1998-04-10 Vehicule du pool sanguin pour agents d'imagerie lipophiles
EP98918097A EP0973553A2 (fr) 1997-04-11 1998-04-10 Vehicule du pool sanguin pour agents d'imagerie lipophiles
AU71087/98A AU7108798A (en) 1997-04-11 1998-04-10 Blood-pool carrier for lipophilic imaging agents
JP54410898A JP2001524957A (ja) 1997-04-11 1998-04-10 親油性画像診断剤用の血液プール運搬体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4330597P 1997-04-11 1997-04-11
US60/043,305 1997-04-11

Publications (2)

Publication Number Publication Date
WO1998046275A2 WO1998046275A2 (fr) 1998-10-22
WO1998046275A3 true WO1998046275A3 (fr) 1999-01-28

Family

ID=21926484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007239 WO1998046275A2 (fr) 1997-04-11 1998-04-10 Vehicule du pool sanguin pour agents d'imagerie lipophiles

Country Status (6)

Country Link
EP (1) EP0973553A2 (fr)
JP (1) JP2001524957A (fr)
KR (1) KR20010006195A (fr)
AU (1) AU7108798A (fr)
CA (1) CA2286138A1 (fr)
WO (1) WO1998046275A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001300287A (ja) * 2000-04-20 2001-10-30 Nof Corp パーフルオロカーボン乳化製剤
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
WO2010057203A2 (fr) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Particules de hdl pour administration d'acides nucléiques
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019738A1 (fr) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Methode de traitement de tissus infectes
WO1994007466A1 (fr) * 1992-10-07 1994-04-14 Liposome Technology, Inc. Compositions de traitement de tissus enflammes
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
WO1996034598A1 (fr) * 1995-05-03 1996-11-07 Polymasc Pharmaceuticals Plc Inclusion dans des tissus
WO1997013499A1 (fr) * 1995-10-11 1997-04-17 The University Of British Columbia Formulations de liposomes a base de mitoxantrone
WO1997040858A1 (fr) * 1996-04-30 1997-11-06 Imarx Pharmaceutical Corp. Nouveau melange de lipides dispersibles et ses utilisations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019738A1 (fr) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Methode de traitement de tissus infectes
WO1994007466A1 (fr) * 1992-10-07 1994-04-14 Liposome Technology, Inc. Compositions de traitement de tissus enflammes
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
WO1996034598A1 (fr) * 1995-05-03 1996-11-07 Polymasc Pharmaceuticals Plc Inclusion dans des tissus
WO1997013499A1 (fr) * 1995-10-11 1997-04-17 The University Of British Columbia Formulations de liposomes a base de mitoxantrone
WO1997040858A1 (fr) * 1996-04-30 1997-11-06 Imarx Pharmaceutical Corp. Nouveau melange de lipides dispersibles et ses utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIRPOTIN, DMITRI ET AL: "Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol)", FEBS LETT. (1996), 388(2,3), 115-118 CODEN: FEBLAL;ISSN: 0014-5793, XP002080855 *
SACHSE A ET AL: "Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes.", INVEST RADIOL, JAN 1997, 32 (1) P44-50, UNITED STATES, XP002080856 *
SCHERPHOF G L ET AL: "INTRAHEPATIC DISTRIBUTION OF LONG-CIRCULATING LIPOSOMES CONTAINING POLY(ETHYLENE GLYCOL) DISTEAROYL PHOSPHATIDYLETHANOLAMINE", JOURNAL OF LIPOSOME RESEARCH, vol. 4, no. 1, January 1994 (1994-01-01), pages 213 - 228, XP002055537 *
SCHNEIDER T M: "Surface modification of continuously extruded contrast-carrying liposomes: Effect on their physical properties.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), 1996, XP002080857 *

Also Published As

Publication number Publication date
EP0973553A2 (fr) 2000-01-26
KR20010006195A (ko) 2001-01-26
WO1998046275A2 (fr) 1998-10-22
CA2286138A1 (fr) 1998-10-22
AU7108798A (en) 1998-11-11
JP2001524957A (ja) 2001-12-04

Similar Documents

Publication Publication Date Title
US6333021B1 (en) Microcapsules, method of making and their use
EP0593624B1 (fr) Perfectionnements apportes aux agents de contraste
AU630030B2 (en) Stable microbubbles suspensions injectable into living organisms
PL331487A1 (en) Gases microencapsulated in polymerolipides for use as imaging agents
CA2250970C (fr) Emulsions de cyclosporine
US5792445A (en) Polymers and copolymers of acrylic acid MRI of the digestive tract of patients
JP2968588B2 (ja) Ｎｍｒ画像形成のための粒子及び製造方法
Palin et al. The oral absorption of cefoxitin from oil and emulsion vehicles in rats
EP0167825A3 (en) Lipid nano pellets as drug carriers for oral administration
WO1998057667B1 (fr) Procedes d'imagerie photoacoustique
YU103792A (sh) Kontrasno sredstvo za snimanje ultrazvukom
WO2009049089A1 (fr) Nanoparticules toroïdales dirigées ligand pour thérapie et imagerie de diagnostic
WO1998046275A3 (fr) Vehicule du pool sanguin pour agents d'imagerie lipophiles
Elbaz et al. Positively charged submicron emulsions—a new type of colloidal drug carrier
US20020168321A1 (en) Administrable mri compositions for enhancing the contrast between regions in organs
Povey et al. Trapping of chemical carcinogens with magnetic polyethyleneimine microcapsules: III. In vivo trapping of electrophiles from N-methyl-N-nitrosourea and recovery from feces
EP0759785B1 (fr) Suspensions de liposomes utilisees comme produit de contraste de visualisation du pool sanguin intracardiaque
Santaella et al. Molecular order and mobility within liposomal membrane made from highly fluorinated phospholipids
EP1054303A3 (fr) Appareil de développement et appareil de formation d'images
Ishii et al. Interaction between erythrocytes from various animals and emulsions stabilized with various lecithins
zu Düttingdorf et al. Isolation and lipid composition of apical and basolateral membranes of colonic segments of guinea pig
RU96119939A (ru) Липосомы
MXPA96002697A (en) Microcapsules, manufacturing method and its

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2286138

Country of ref document: CA

Ref country code: CA

Ref document number: 2286138

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019997009275

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 544108

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998918097

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998918097

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997009275

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998918097

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997009275

Country of ref document: KR